| INTRODUCTION
Coeliac disease is common, currently affecting approximately 1% of North America and Western Europe, 1 and the prevalence is stable or rising. [2] [3] [4] However despite this, one study estimates that 83% of cases in the USA remain undiagnosed. 5 Explanations for this include the nonspecific symptoms and signs as well as a lack of awareness of coeliac disease among care providers. In addition, current strategies for clinical detection may be suboptimal in clinical practice.
Identification of coeliac disease in clinical practice is driven by testing symptomatic patients or by case finding. Case finding is defined as the practice of testing individuals who are at an increased risk for the disease, due primarily to the presence of symptoms or conditions associated with coeliac disease. [6] [7] [8] Case finding has been reported to increase coeliac disease diagnosis by 32-43 fold in the primary care setting, 8 however, there is increasing suspicion that case finding may not be effective, and that indications to test, such as gastrointestinal symptoms, have poor diagnostic accuracy in identifying coeliac disease. [9] [10] [11] [12] The US Preventive Services Task Force recently released a recommendation statement that there is insufficient evidence to support "targeted screening" of asymptomatic persons. 13, 14 Determining the association between indications to test and having undiagnosed coeliac disease and the frequency of testing in the general population is crucial to assess the efficacy of current strategies to improve detection rates. While a recent study on the morbidity of undiagnosed cases of coeliac disease between the ages of 18 and 50 in Olmsted County reported on the lack of typical symptoms in this cohort, the study did not report on many of the nonclassical symptoms recommended as indications to test by our current guidelines. 6 To fully evaluate the potential efficacy of case finding, we therefore aimed to look at the adult population of undiagnosed coeliac disease, including those over 50, and age-and gender-matched controls, to assess the relationship of serologic status and indications to test prior to serology testing, including both classical and nonclassical symptoms, as well as the frequency of testing for coeliac disease in the community. In addition, to address the paucity of information on the natural history of undiagnosed coeliac disease, we evaluated how often individuals with undiagnosed coeliac disease developed clinically apparent indicators for coeliac disease testing.
2 | ME TH ODS Cases and controls were combined into one list and reviewed by investigators blinded to serological results.
| Indications for clinical testing
The indications for clinical testing included were consistent with current guidelines and prior research. 6, 8, 16, 17 These indications include "classic" coeliac disease symptoms, such as malabsorption, diarrhoea, and weight loss and "nonclassic" coeliac disease symptoms, such as osteoporosis, anaemia, unexplained elevation of liver enzymes, associated disorders such as autoimmune diseases, and a positive family history. 18 (Table 1) 
| Data collection
The medical record of cases and controls, which included in-patient, out-patient and emergency department documentation, was systematically reviewed by a physician (I. H.) blinded to serologic status. (Table S1) , and the data were stored as a limited data set in a secure encrypted archive.
Indications for clinical testing, except for "incidental discovery of villous atrophy" and "family history of coeliac disease," were found by reviewing the problem list from each clinical note in the medical record. These lists were generated by compiling the problems and diagnoses detailed in the care provider's listed impression and plan. The data on clinical testing and indications were combined with serologic status using the study ID and analysis was performed in a limited data set to preserve patient anonymity. Participants were not specifically identified or contacted.
| Ethical issues
This study was approved by the Mayo Foundation Institutional
Review Board. The study was performed on a limited data set that preserved subject anonymity by blinding the investigators to the identity of cases. Only subjects who provided research authorisation were included. No subject contacts were permitted by the Institutional Review Board.
| Statistical analysis
The prevalence and 95% exact confidence interval (CI) for undiagnosed coeliac disease among our sampled community was estimated with the Clopper-Pearson method. The cumulative rate of subsequent clinical coeliac disease diagnosis was estimated using the KaplanMeier product limit.
To estimate the efficacy of case finding, we assessed the frequency of indications for clinical testing prior to the date the stored serum was drawn in both cases of undiagnosed coeliac disease and their age-and gender-matched controls. Conditional logistic regression was used to generate odds ratios with corresponding 95% CI.
To estimate the natural history of undiagnosed coeliac disease, the rate of development of indications to test after collection of the blood sample was calculated. For each indication to test, the total number of individuals presenting with that indication after serum collection as well as the total number of years from serum collection to symptom development was determined. Individuals who had the indication prior to serum collection were excluded for that indication's rate calculation, although they were included for other indications. Hazard ratios and nonparametric log-rank tests were calculated as appropriate.
All analyses were done using SAS statistical software version 9.4
(SAS Institute, Cary, North Carolina). An alpha level of 0.05 was used to define statistical significance without correction for multiple comparisons. Agreement between the 2 investigators was quantified using the pooled estimator of the kappa statistic.
| RESULTS
Of the 47 557 serum samples, 408 cases of undiagnosed coeliac disease were identified, with a prevalence of undiagnosed coeliac disease 
| Efficacy of case finding
Roughly 40% of all individuals (n = 306; 38.3%) had at least one 
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There were four cases of Down syndrome and two cases of family history of coeliac disease in those with undiagnosed coeliac disease and zero cases of either in controls.
| Frequency of testing and coeliac disease diagnosis in the community
Less than 5% (n = 35; 4.4%) were tested for coeliac disease by a provider in the community prior to our serologic testing. Testing was less in undiagnosed coeliac disease, with 9 (2.3%) tested as opposed to 26 (6.5%) controls (OR = 0.32; 95% CI, 0.14-0.71, P = 0.005). Serologic testing was similar between the two groups (OR = 0.583, 95% CI 0.23-1.48, P = 0.26), however, small bowel biopsies were significantly more likely in controls (OR = 0.06, 95% CI 0.01-0.42, P = 0.005) (Figure 3 ). Symptoms and signs that were associated with receiving a diagnosis of coeliac disease in the community included: vitamin deficiency (P = 0.01), anaemia (P = 0.001), iron deficiency (P = 0.001), diarrhoea (P = 0.001), chronic diarrhoea (0.001), recurrent abdominal pain (P = 0.02), bloating (P = 0.001), incidental villous atrophy (P = 0.001), dermatitis herpetiformis (P = 0.002), hypothyroidism (P = 0.003), infertility (P = 0.001), chronic fatigue (P = 0.03), family history of coeliac disease (P = 0.001), type I diabetes mellitus (P = 0.004) and vitiligo (P = 0.01). 
| Natural history of undiagnosed coeliac disease

| Validity of data collection
The pooled kappa statistic for agreement between the 2 investigators on collected variables was 0.966, indicating near perfect agreement.
| DISCUSSION
This study evaluated the utility of case finding to detect coeliac disease in a North American community as well as the development of indications for testing for coeliac disease. The major findings of this study are (1) the majority of currently used indications to test for coeliac disease do not predict undiagnosed coeliac disease, (2) the rate of testing for coeliac disease was low in both groups but was more likely in controls and (3) nosed. This is consistent with prior observations. 9, 20 Few relationships were statistically significant between serologic status and indications for clinical testing, even without controlling for multiple comparisons. Hypothyroidism was more likely among undiagnosed coeliac disease, which is congruent with prior reports suggesting it is one of the most common autoimmune diseases associated with coeliac disease. 18 Other autoimmune diseases were more likely in coeliac disease but were not statistically significant. The low frequency of testing in the community is consistent with prior observations. 19 Testing was significantly more likely among controls, which may be explained by the higher frequency of dyspepsia and chronic diarrhoea in this group than in those with hidden coeliac disease. With the high prevalence of indications to test in County was driven by case finding or usual practice.
Our study suggests that case finding is likely an ineffective strategy to identify most cases of undiagnosed coeliac disease in the general population, raising the question of how to detect coeliac disease. While there are proponents for mass screening, this strategy remains controversial. There is currently insufficient evidence on the cost-effectiveness and benefit of identifying and treating asymptomatic coeliac disease; 19 it is likely that mass screening will identify both symptomatic and asymptomatic coeliac disease. 11, 21 Current strategies based on case finding will not. Along with the unclear benefits of identifying asymptomatic cases of coeliac disease, there is also the possibility of harm such as over-diagnosis.
Alternatives to mass screening and case finding should be actively Our study has several potential limitations. Undiagnosed coeliac disease was identified through sequential serology, and duodenal biopsies were not available due to study limitations that did not permit contact with subjects. However, prior studies have shown sequential serology with immunoglobulin A tissue transglutaminase and endomysial antibodies to be effective at identifying coeliac disease in large populations. 12 The Kalixanda study found that almost all individuals with positive sequential serologic testing had histology consistent with coeliac disease. 12 This technique has been used in a number of prior studies. 5, 15 In addition, serology was tested at a random point of time in the subject's medical history, and there has been evidence of regression of seropositivity in the paediatric population. 23 Another potential limitation is that we did not identify immunoglobu- However, during review of the medical record, there was no report of gluten-free diets. In addition, the collection years for the serologic samples predates the gluten avoidance trend. 24 Family history was gathered from Patient Family History forms which did not specifically ask about coeliac disease. Because of this, we were likely unable to accurately assess the frequency of family history, which has previously been found to be highly indicative of being at risk for coeliac disease. 25 However, our study method reflects the indications recognised during a healthcare visit, and therefore reflects case finding taking place in the studied community. Finally, a single investigator collected the entire data set;
however, the reliability of this method was validated by the near perfect agreement with the subset of data collected by the second investigator.
In conclusion, this study found that case finding was ineffective at discriminating between those with and without undiagnosed coeliac disease. Individuals with undiagnosed coeliac disease were more likely to develop indications to test such as osteoporosis and autoimmune conditions. If further studies confirm the ineffectiveness of case finding, alternative methods of detecting symptomatic coeliac disease are needed.
